These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 12138687

  • 1. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P, Stipa E, La Presa M, Bianchi M, Di Giulio C, Stasi R, Amadori S.
    Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
    [Abstract] [Full Text] [Related]

  • 2. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 3. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 4. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

  • 5. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH.
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [Abstract] [Full Text] [Related]

  • 7. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR, Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [Abstract] [Full Text] [Related]

  • 8. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z, Yang R.
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [Abstract] [Full Text] [Related]

  • 9. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S.
    Blood Cells Mol Dis; 2000 Dec; 26(6):582-6. PubMed ID: 11112391
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.
    Parodi E, Rivetti E, Amendola G, Bisogno G, Calabrese R, Farruggia P, Giordano P, Matarese SM, Nardi M, Nobili B, Notarangelo LD, Russo G, Vimercati C, Zecca M, De Mattia D, Ramenghi U.
    Br J Haematol; 2009 Feb; 144(4):552-8. PubMed ID: 19036077
    [Abstract] [Full Text] [Related]

  • 11. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R.
    Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
    [Abstract] [Full Text] [Related]

  • 12. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
    Riksen NP, Keuning JJ, Vreugdenhil G.
    Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
    [Abstract] [Full Text] [Related]

  • 13. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
    Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina M, Ippoliti M, Ferrara F, Patriarca F, Avanzini MA, Regazzi M, Baccarani M, Isola M, Soldano F, Fanin R.
    Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
    [Abstract] [Full Text] [Related]

  • 14. Rituximab treatment for symptomatic chronic ITP.
    Tamminga RY, Bruin MC.
    Pediatr Blood Cancer; 2006 Oct 15; 47(5 Suppl):714-6. PubMed ID: 16933264
    [Abstract] [Full Text] [Related]

  • 15. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.
    J Intern Med; 2009 Nov 15; 266(5):484-91. PubMed ID: 19549092
    [Abstract] [Full Text] [Related]

  • 16. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R, Pagano A, Stipa E, Amadori S.
    Blood; 2001 Aug 15; 98(4):952-7. PubMed ID: 11493438
    [Abstract] [Full Text] [Related]

  • 17. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
    Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA.
    Ann Hematol; 2009 Mar 15; 88(3):239-43. PubMed ID: 18704420
    [Abstract] [Full Text] [Related]

  • 18. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
    Latifzadeh SZ, Entezari V.
    Clin Appl Thromb Hemost; 2006 Oct 15; 12(4):489-92. PubMed ID: 17000895
    [Abstract] [Full Text] [Related]

  • 19. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N, Evangelista ML, Amadori S, Stasi R.
    Curr Opin Hematol; 2007 Nov 15; 14(6):642-6. PubMed ID: 17898569
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.
    Br J Haematol; 2004 Apr 15; 125(2):232-9. PubMed ID: 15059147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.